CaboCombo international real-world study: Second interim analysis of cabozantinib plus nivolumab (CaboNivo) as first-line (1L) treatment for advanced renal cell carcinoma (aRCC)

Barthelemy, P.; Gimel, P.; Bailly, S.; Geoffrois, L.; Goujon, M.; Laramas, M.; Park, S. H.; Saldana, C.; Dutailly, P.; Perrot, V.; Bigot, P.

doi:10.1016/j.annonc.2025.08.3241

상세 보기

CaboCombo international real-world study: Second interim analysis of cabozantinib plus nivolumab (CaboNivo) as first-line (1L) treatment for advanced renal cell carcinoma (aRCC)

Barthelemy, P.;
Gimel, P.;
Bailly, S.;
Geoffrois, L.;
Goujon, M.;
외 6명

Citations

WEB OF SCIENCE

0

Citations

SCOPUS

0

제목: CaboCombo international real-world study: Second interim analysis of cabozantinib plus nivolumab (CaboNivo) as first-line (1L) treatment for advanced renal cell carcinoma (aRCC)

저자: Barthelemy, P.; Gimel, P.; Bailly, S.; Geoffrois, L.; Goujon, M.; Laramas, M.; Park, S. H.; Saldana, C.; Dutailly, P.; Perrot, V.; Bigot, P.

DOI: 10.1016/j.annonc.2025.08.3241

발행일: 2025-09

유형: Meeting Abstract

저널명: Annals of Oncology

권: 36

ScholarWorks@성균관대학교

상세 보기